Primary	Absolute number and point estimate (with 95% confidence intervals (CIs)) of the proportion of enrolled participants who are diagnosed with microbiologically confirmed TB and are starting TB treatment within 7 days of enrolment
Secondary
-Diagnosis	Time to bacteriological confirmation of TB (up to 60 days) from enrolment and point estimate with 95% CIs of the proportion of patients treated for TB who are diagnosed up to 60 days from enrolment (microbiologically and/or clinically)
-Treatment	Point estimate with 95% CIs of the proportion of participants evaluated for pulmonary TB starting TB treatment with microbiological confirmation within 60 days from enrolment
	Absolute number, and point estimate (with 95% CIs) of the proportion of enrolled participants evaluated for pulmonary TB starting TB treatment regardless of microbiological confirmation within 7 and 60 days from enrolment
	Time to TB treatment initiation for those with microbiological confirmation and for all participants (censored at 60 days) from enrolment
	Point estimate of the proportion of patients with ongoing treatment
-Morbidity	Prevalence of current cough, limited appetite, weakness at 60 days from enrolment
-Cost effectiveness	Estimate of patient costs related to care, number of lost working days, monthly earnings, unit costs of diagnosis and treatment, incremental cost-effectiveness ratio
-Operational characteristics	Proportion of Invalid/Error Truenat MTB-Assay test results and platform failure
-User acceptability	User survey to assess usability